Skip to main content Accessibility help
×
Home

Very long-chain n-3 fatty acids and human health: fact, fiction and the future

  • P. C. Calder (a1) (a2)

Abstract

EPA and DHA appear to be the most important n-3 fatty acids, but roles for n-3 docosapentaenoic acid are now also emerging. Intakes of EPA and DHA are usually low, typically below those recommended. Increased intakes result in higher concentrations of EPA and DHA in blood lipids, cells and tissues. Increased content of EPA and DHA modifies the structure of cell membranes and the function of membrane proteins. EPA and DHA modulate the production of lipid mediators and through effects on cell signalling can alter the patterns of gene expression. Through these mechanisms, EPA and DHA alter cell and tissue responsiveness in a way that often results in more optimal conditions for growth, development and maintenance of health. DHA has vital roles in brain and eye development and function. EPA and DHA have a wide range of physiological roles, which are linked to certain health or clinical benefits, particularly related to CVD, cancer, inflammation and neurocognitive function. The benefits of EPA and DHA are evident throughout the life course. Future research will include better identification of the determinants of variation of responses to increased intake of EPA and DHA; more in-depth dose–response studies of the effects of EPA and DHA; clearer identification of the specific roles of EPA, docosapentaenoic acid and DHA; testing strategies to enhance delivery of n-3 fatty acids to the bloodstream; and exploration of sustainable alternatives to fish-derived very long-chain n-3 fatty acids.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Very long-chain n-3 fatty acids and human health: fact, fiction and the future
      Available formats
      ×

      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Very long-chain n-3 fatty acids and human health: fact, fiction and the future
      Available formats
      ×

      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Very long-chain n-3 fatty acids and human health: fact, fiction and the future
      Available formats
      ×

Copyright

Corresponding author

Corresponding author: P. C. Calder, email pcc@soton.ac.uk

References

Hide All
1. Burdge, GC & Calder, PC (2015) Introduction to fatty acids and lipids. World Rev Nutr Diet 112, 116.
2. Calder, PC & Yaqoob, P (2009) Understanding omega-3 polyunsaturated fatty acids. Postgrad Med 121, 148157.
3. Calder, PC (2014) Very long chain omega-3 (n-3) fatty acids and human health. Eur J Lipid Sci Technol 116, 12801300.
4. Kaur, G, Cameron-Smith, D, Garg, M et al. (2011) Docosapentaenoic acid (22:5n-3): a review of its biological effects. Prog. Lipid Res 50, 2834.
5. Weylandt, KH (2016) Docosapentaenoic acid derived metabolites and mediators – the new world of lipid mediator medicine in a nutshell. Eur J Pharmacol 785, 108115.
6. Blasbalg, TL, Hibbeln, JR, Ramsden, CE et al. (2011) Changes in consumption of omega-3 and omega-6 fatty acids in the United States during the 20th century. Am J Clin Nutr 93, 950962.
7. Arterburn, LM, Hall, EB & Oken, H (2006) Distribution, interconversion, and dose response of n-3 fatty acids in humans. Am J Clin Nutr 83, 1467S1476S.
8. Baker, EJ, Miles, EA, Burdge, GC et al. (2016) Metabolism and functional effects of plant-derived omega-3 fatty acids in humans. Prog Lipid Res 64, 3056.
9. Bolton-Smith, C, Woodward, M & Tavendale, R (1997) Evidence for age-related differences in the fatty acid composition of human adipose tissue, independent of diet. Eur J Clin Nutr 51, 619624.
10. Childs, CE, Romeu-Nadal, M, Burdge, GC et al. (2008) Gender differences in the n-3 fatty acid content of tissues. Proc Nutr Soc 67, 1927.
11. Burdge, GC, Jones, AE & Wootton, SA (2002) Eicosapentaenoic and docosapentaenoic acids are the principal products of alpha-linolenic acid metabolism in young men. Brit J Nutr 88, 355363.
12. Burdge, GC & Wootton, SA (2002) Conversion of alpha-linolenic acid to eicosapentaenoic, docosapentaenoic and docosahexaenoic acids in young women. Brit J Nutr 88, 411420.
13. Vessby, B, Gustafsson, IB, Tengblad, S et al. (2002) Desaturation and elongation of fatty acids and insulin action. Ann NY Acad Sci 967, 183195.
14. Koletzko, B, Lattka, E, Zeilinger, S et al. (2011) Genetic variants of the fatty acid desaturase gene cluster predict amounts of red blood cell docosahexaenoic acid and other polyunsaturated fatty acids in pregnant women: findings from the Avon Longitudinal Study of Parents and Children. Am J Clin Nutr 93, 211219.
15. British Nutrition Foundation (1999) N-3 Fatty Acids and Health. London: British Nutrition Foundation.
16. Calder, PC (2017) Omega-3: the good oil. Nutr Bull 42, 132140.
17. Scientific Advisory Committee on Nutrition/Committee on Toxicity (2004) Advice on Fish Consumption: Benefits and Risks. London: TSO.
18. Meyer, BJ, Mann, NJ, Lewis, JL et al. (2003) Dietary intakes and food sources of omega-6 and omega-3 polyunsaturated fatty acids. Lipids 38, 391398.
19. Howe, P, Meyer, B, Record, S et al. (2006) Dietary intake of long-chain omega-3 polyunsaturated fatty acids: contribution of meat sources. Nutrition 22, 4753.
20. Rahmawaty, S, Charlton, K, Lyons-Wall, P et al. (2013) Dietary intake and food sources of EPA, DPA and DHA in Australian children. Lipids 48, 869877.
21. Stubbs, CD & Smith, AD (1984) The modification of mammalian membrane polyunsaturated fatty acid composition in relation to membrane fluidity and function. Biochim Biophys Acta 779, 89137.
22. Brenner, RR (1984) Effect of unsaturated fatty acids on membrane structure and enzyme kinetics. Prog Lipid Res 23, 6996.
23. Murphy, MG (1990) Dietary fatty acids and membrane protein function. J Nutr Biochem 1, 6879.
24. Browning, LM, Walker, CG, Mander, AP et al. (2012) Incorporation of eicosapentaenoic and docosahexaenoic acids into lipid pools when given as supplements providing doses equivalent to typical intakes of oily fish. Am J Clin Nutr 96, 748758.
25. Miles, EA, Noakes, PS, Kremmyda, LS et al. (2011) The Salmon in Pregnancy Study: study design, subject characteristics, maternal fish and marine n-3 fatty acid intake, and marine n-3 fatty acid status in maternal and umbilical cord blood. Am J Clin Nutr 94, 1986S1992S.
26. Healy, DA, Wallace, FA, Miles, EA et al. (2000) The effect of low to moderate amounts of dietary fish oil on neutrophil lipid composition and function. Lipids 35, 763768.
27. Skinner, ER, Watt, C, Besson, JA et al. (1993) Differences in the fatty acid composition of the grey and white matter of different regions of the brains of patients with Alzheimer's disease and control subjects. Brain 116, 717725.
28. Makrides, M, Neumann, MA, Byard, RW et al. (1994) Fatty acid composition of brain, retina, and erythrocytes in breast- and formula-fed infants. Am J Clin Nutr 60, 189194.
29. Harris, WS, Sands, SA, Windsor, SL et al. (2004) Omega-3 fatty acids in cardiac biopsies from heart transplantation patients: correlation with erythrocyes and response to supplementation. Circulation 110, 16451649.
30. Metcalf, RG, James, MJ, Gibson, RA et al. (2007) Effects of fish-oil supplementation on myocardial fatty acids in humans. Am J Clin Nutr 85, 12221228.
31. McGlory, C, Galloway, SD, Hamilton, DL et al. (2014) Temporal changes in human skeletal muscle and blood lipid composition with fish oil supplementation. Prostagland Leukotr Essent Fatty Acids 90, 199206.
32. Smith, GI, Atherton, P, Reeds, DN et al. (2011) Omega-3 polyunsaturated fatty acids augment the muscle protein anabolic response to hyperinsulinaemia-hyperaminoacidaemia in healthy young and middle-aged men and women. Clin Sci 121, 267278.
33. Araya, J, Rodrigo, R, Videla, LA et al. (2004) Increase in long-chain polyunsaturated fatty acid n-6/n-3 ratio in relation to hepatic steatosis in patients with non-alcoholic fatty liver disease. Clin Sci 106, 635643.
34. Elizondo, A, Araya, J, Rodrigo, R et al. (2007) Polyunsaturated fatty acid pattern in liver and erythrocyte phospholipids from obese patients. Obesity 15, 2431.
35. Hillier, K, Jewell, R, Dorrell, L et al. (1991) Incorporation of fatty acids from fish oil and olive oil into colonic mucosal lipids and effects upon eicosanoid synthesis in inflammatory bowel disease. Gut 32, 11511155.
36. Safarinejad, MR (2011) Effect of omega-3 polyunsaturated fatty acid supplementation on semen profile and enzymatic anti-oxidant capacity of seminal plasma in infertile men with idiopathic oligoasthenoteratospermia: a double-blind, placebo-controlled, randomised study. Andrologia 43, 3847.
37. Crawford, MA, Casperd, NM & Sinclair, AJ (1976) The long chain metabolites of linoleic and linolenic acids in liver and brain in herbivores and carnivores. Comp Biochem Physiol 54B, 395401.
38. Anderson, RE (1970) Lipids of ocular tissues. IV. A comparison of the phospholipids from the retina of six mammalian species. Exp Eye Res 10, 339344.
39. von Schacky, C, Fischer, S & Weber, PC (1985) Long term effects of dietary marine ω−3 fatty acids upon plasma and cellular lipids, platelet function, and eicosanoid formation in humans. J Clin Invest 76, 16261631.
40. Harris, WS, Windsor, SL & Dujovne, CA (1991) Effects of four doses of n-3 fatty acids given to hyperlipidemic patients for six months. J Am Coll Nutr 10, 220227.
41. Marsen, TA, Pollok, M, Oette, K et al. (1992) Pharmacokinetics of omega-3 fatty acids during ingestion of fish oil preparations. Prostagland Leukotr Essent Fatty Acids 46, 191196.
42. Blonk, MC, Bilo, HJ, Popp-Snijders, C et al. (1990) Dose-response effects of fish oil supplementation in healthy volunteers. Am J Clin Nutr 52, 120127.
43. Katan, MB, Deslypere, JP, van Birgelen, APJM et al. (1997) Kinetics of the incorporation of dietary fatty acids into serum cholesteryl esters, erythrocyte membranes and adipose tissue: an 18 month controlled study. J Lipid Res 38, 20122022.
44. Yaqoob, P, Pala, HS, Cortina-Borja, M et al. (2000) Encapsulated fish oil enriched in α-tocopherol alters plasma phospholipid and mononuclear cell fatty acid compositions but not mononuclear cell functions. Eur J Clin Invest 30, 260274.
45. Rees, D, Miles, EA, Banerjee, T et al. (2006) Dose-related effects of eicosapentaenoic acid on innate immune function in healthy humans: a comparison of young and older men. Am J Clin Nutr 83, 331342.
46. Faber, J, Berkhout, M, Vos, AP et al. (2011) Supplementation with a fish oil-enriched, high-protein medical food leads to rapid incorporation of EPA into white blood cells and modulates immune responses within one week in healthy men and women. J Nutr 141, 964970.
47. Popp-Snijders, C, Schouten, JA, van Blitterswijk, WJ et al. (1986) Changes in membrane lipid composition of human erythrocytes after dietary supplementation of (n-3) fatty acids: maintenance of membrane fluidity. Biochim Biophys Acta 854, 3137.
48. Sanders, TAB & Roshanai, F (1983) The influence of different types of ω3 polyunsaturated fatty acids on blood lipids and platelet function in healthy volunteers. Clin Sci 64, 9199.
49. Sperling, RI, Benincaso, AI, Knoell, CT et al. (1993) Dietary ω−3 polyunsaturated fatty acids inhibit phosphoinositide formation, and chemotaxis in neutrophils. J Clin Invest 91, 651660.
50. Sorensen, LS, Rasmussen, HH, Aardestrup, IV et al. (2014) Rapid incorporation of ω−3 fatty acids into colonic tissue after oral supplementation in patients with colorectal cancer: a randomized, placebo-controlled intervention trial. J Parent Ent Nutr 38, 617624.
51. Calder, PC (2012) Mechanisms of action of (n-3) fatty acids. J Nutr 142, 592S599S.
52. Calder, PC (2013) Omega-3 polyunsaturated fatty acids and inflammatory processes: nutrition or pharmacology? Brit J Clin Pharmacol 75, 645662.
53. Calder, PC (2013) n-3 Fatty acids, inflammation and immunity: new mechanisms to explain old actions. Proc Nutr Soc 72, 326336.
54. Calder, PC, Yaqoob, P, Harvey, DJ et al. (1994) The incorporation of fatty acids by lymphocytes and the effect on fatty acid composition and membrane fluidity. Biochem J 300, 509518.
55. Miles, EA & Calder, PC (1998) Modulation of immune function by dietary fatty acids. Proc Nutr Soc 57, 277292.
56. Niu, SL, Mitchell, DC, Lim, SY et al. (2004) Reduced G protein-coupled signaling efficiency in retinal rod outer segments in response to n-3 fatty acid deficiency. J Biol Chem 279, 3109831104.
57. Pike, LJ (2003) Lipid rafts: bringing order to chaos. J Lipid Res 44, 655667.
58. Simons, K & Gerl, MJ (2010) Revitalizing membrane rafts: new tools and insights. Nat Rev Mol Cell Biol 11, 688699.
59. Yaqoob, P (2009) The nutritional significance of lipid rafts. Annu Rev Nutr 29, 257282.
60. Calder, PC & Yaqoob, P (2007) Lipid rafts – Composition, characterization and controversies. J Nutr 137, 545547.
61. Hou, TY, McMurray, DN & Chapkin, RS (2016) Omega-3 fatty acids, lipid rafts, and T cell signaling. Eur J Pharmacol 785, 29.
62. Calder, PC (2013) Fat chance to enhance B cell function. J Leuk Biol 93, 457459.
63. Calder, PC (2013) Long chain fatty acids and gene expression in inflammation and immunity. Curr Opin Clin Nutr Metab Care 16, 425433.
64. Novak, TE, Babcock, TA, Jho, DH et al. (2003) NF-kappa B inhibition by omega-3 fatty acids modulates LPS-stimulated macrophage TNF-alpha transcription. Am J Physiol 284, L84L89.
65. Krey, G, Braissant, O, L'Horset, F et al. (1997) Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay. Mol Endocrinol 11, 779791.
66. Marion-Letellier, R, Savoye, G & Ghosh, S (2016) Fatty acids, eicosanoids and PPAR gamma. Eur J Pharmacol 785, 4449.
67. Clarke, SD (2004) The multi-dimensional regulation of gene expression by fatty acids: polyunsaturated fats as nutrient sensors. Curr Opin Lipidol 15, 1318.
68. Lapillonne, A, Clarke, SD & Heird, WC (2004) Polyunsaturated fatty acids and gene expression. Curr Opin Clin Nutr Metab Care 7, 151156.
69. Jump, DB (2002) Dietary polyunsaturated fatty acids and regulation of gene transcription. Curr Opin Lipidol 13, 1551564.
70. Jump, DB (2008) N-3 polyunsaturated fatty acid regulation of hepatic gene transcription. Curr Opin Lipidol 19, 242247.
71. Deckelbaum, RJ, Worgall, TS & Seo, T (2006) N-3 fatty acids and gene expression. Am J Clin Nutr 83, 1520S1525S.
72. Calder, PC (2011) Fatty acids and inflammation: the cutting edge between food and pharma. Eur J Pharmacol 668, S50S58.
73. Lewis, RA, Austen, KF & Soberman, RJ (1990) Leukotrienes and other products of the 5-lipoxygenase pathway: biochemistry and relation to pathobiology in human diseases. N Engl J Med 323, 645655.
74. Tilley, SL, Coffman, TM & Koller, BH (2001) Mixed messages: modulation of inflammation and immune responses by prostaglandins and thromboxanes. J Clin Invest 108, 1523.
75. Wada, M, DeLong, CJ, Hong, YH et al. (2007) Enzymes and receptors of prostaglandin pathways with arachidonic acid-derived versus eicosapentaenoic acid-derived substrates and products. J Biol Chem 282, 2225422266.
76. Moncada, S & Vane, JR (1979) The role of prostacyclin in vascular tissue. Fed Proc 38, 6871.
77. Bannenberg, G & Serhan, CN (2010) Specialized pro-resolving lipid mediators in the inflammatory response: an update. Biochim Biophys Acta Mol Cell Biol Lipids 1801, 12601273.
78. Serhan, CN, Chiang, N & van Dyke, TE (2008) Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat Rev Immunol 8, 349361.
79. Serhan, CN & Chiang, N (2013) Resolution phase lipid mediators of inflammation: agonists of resolution. Curr Opin Pharmacol 13, 632640.
80. Dalli, J, Colas, RA & Serhan, CN (2013) Novel n-3 immunoresolvents: structures and roles. Sci Rep 3, 1940.
81. Calder, PC (2015) Marine omega-3 fatty acids and inflammatory processes: effects, mechanisms and clinical relevance. Biochim Biophys Acta 1851, 469484.
82. Oh, DY, Talukdar, S, Bae, EJ et al. (2010) GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects. Cell 142, 687698.
83. Dyerberg, J, Bang, HO, Stoffersen, E et al. (1978) Eicosapentaenoic acid and prevention of thrombosis and atherosclerosis. Lancet ii, 117119.
84. Kromann, N & Green, A (1980) Epidemiological studies in the Upernavik District, Greenland. Acta Med Scand 208, 401406.
85. Bjerregaard, P & Dyerberg, J (1988) Mortality from ischemic heart disease and cerebrovascular disease in Greenland. Int J Epidemiol 17, 514519.
86. Newman, WP, Middaugh, JP, Propst, MT et al. (1993) Atherosclerosis in Alaska Natives and non-natives. Lancet 341, 10561057.
87. Bang, HO, Dyerberg, J & Hjorne, N (1976) The composition of foods consumed by Greenland Eskimos. Acta Med Scand 200, 6973.
88. Yano, K, MacLean, CJ, Reed, DM et al. (1988) A comparison of the 12-year mortality and predictive factors of coronary heart disease among Japanese men in Japan and Hawaii. Am J Epidemiol 127, 476487.
89. Kris-Etherton, PM, Harris, WS & Appel, LJ (2002) Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. American Heart Association Nutrition Committee. Circulation 106, 27472757.
90. von Schacky, C (2004) Omega-3 fatty acids and cardiovascular disease. Curr Opin Clin Nutr Metab Care 7, 131136.
91. London, B, Albert, C, Anderson, M et al. (2007) Omega-3 fatty acids and cardiac arrhythmias: prior studies and recommendations for future research: a report from the National Heart, Lung, and Blood Institute and Office Of Dietary Supplements Omega-3 Fatty Acids and their Role in Cardiac Arrhythmogenesis Workshop. Circulation 116, e320e335.
92. Wang, C, Harris, WS, Chung, M et al. (2006) n-3 Fatty acids from fish or fish-oil supplements, but not alpha-linolenic acid, benefit cardiovascular disease outcomes in primary- and secondary-prevention studies: a systematic review. Am J Clin Nutr 84, 517.
93. Calder, PC (2004) n-3 Fatty acids and cardiovascular disease: evidence explained and mechanisms explored. Clin Sci 107, 111.
94. Chowdhury, R, Warnakula, S, Kunutsor, S et al. (2014) Association of dietary, circulating, and supplement fatty acids with coronary risk: a systematic review and meta-analysis. Ann Intern Med 160, 398406.
95. Del Gobbo, LC, Imamura, F, Aslibekyan, S et al. (2016) ω−3 Polyunsaturated fatty acid biomarkers and coronary heart disease: pooling project of 19 cohort studies. JAMA Intern Med 176, 11551166.
96. Calder, PC (2017) New evidence that omega-3 fatty acids have a role in primary prevention of coronary heart disease. J Pub Health Emerg 1, 35.
97. Harris, WS (1996) N-3 fatty acids and lipoproteins: comparison of results from human and animal studies. Lipids 31, 243252.
98. Saravanan, P, Davidson, NC, Schmidt, EB et al. (2010) Cardiovascular effects of marine omega-3 fatty acids. Lancet 376, 540550.
99. De Caterina, R (2011) n-3 fatty acids in cardiovascular disease. N Engl J Med 364, 24392450.
100. Balk, EM, Lichtenstein, AH, Chung, M et al. (2006) Effects of omega-3 fatty acids on serum markers of cardiovascular disease risk: a systematic review. Atherosclerosis 189, 1930.
101. Leslie, MA, Cohen, DJ, Liddle, DM et al. (2015) A review of the effect of omega-3 polyunsaturated fatty acids on blood triacylglycerol levels in normolipidemic and borderline hyperlipidemic individuals. Lipids Health Dis 14, 53.
102. AbuMweis, S, Jew, S, Tayyem, R et al. (2017) Eicosapentaenoic acid and docosahexaenoic acid containing supplements modulate risk factors for cardiovascular disease: a meta-analysis of randomised placebo-control human clinical trials. J Hum Nutr Diet (In the Press).
103. Mori, TA, Burke, V, Puddey, IB et al. (2000) Purified eicosapentaenoic and docosahexaenoic acids have differential effects on serum lipids and lipoproteins, LDL particle size, glucose, and insulin in mildly hyperlipidemic men. Am J Clin Nutr 71, 10851094.
104. Burr, ML, Fehily, AM, Gilbert, JF et al. (1989) Effects of changes in fat, fish and fibre intake on death and myocardial reinfarction: diet and reinfarction trial (DART). Lancet ii, 757761.
105. Anonymous (1999) Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet 354, 447455.
106. Marchioli, R, Barzi, F, Bomba, E et al. (2002) Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction - Time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione. Circulation 105, 18971903.
107. Yokoyama, M, Origasa, H, Matsuzaki, M et al. (2007) Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet 369, 10901098.
108. Gissi-HF Investigators, Tavazzi, L, Maggioni, AP, Marchioli, R et al. (2008). Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 372, 12231230.
109. Bucher, HC, Hengstler, P, Schindler, C et al. (2002) N-3 polyunsaturated fatty acids in coronary heart disease: a meta-analysis of randomized controlled trials. Am J Med 112, 298304.
110. Studer, M, Briel, M, Leimenstoll, B et al. (2005) Effect of different antilipidemic agents and diets on mortality: a systematic review. Arch Intern Med 165, 725730.
111. Leon, H, Shibata, MC, Sivakumaran, S et al. (2009) Effect of fish oil on arrhythmias and mortality: systematic review. Brit Med J 338, a2931.
112. Harris, WS, Miller, M, Tighe, AP et al. (2008) Omega-3 fatty acids and coronary heart disease risk: clinical and mechanistic perspectives. Atherosclerosis 197, 1224.
113. Xin, W, Wei, W & Li, XY (2013) Short-term effects of fish-oil supplementation on heart rate variability in humans: a meta-analysis of randomized controlled trials. Am J Clin Nutr 97, 926935.
114. Leaf, A & Xiao, YF (2001) The modulation of ionic currents in excitable tissues by n-3 polyunsaturated fatty acids. J Memb Biol 184, 263271.
115. Thies, F, Garry, JMC, Yaqoob, P et al. (2003) Association of n-3 polyunsaturated fatty acids with stability of atherosclerotic plaques: a randomised controlled trial. Lancet 361, 477485.
116. Cawood, AL, Ding, R, Napper, FL et al. (2010) Eicosapentaenoic acid (EPA) from highly concentrated n-3 fatty acid ethyl esters is incorporated into advanced atherosclerotic plaques and higher plaque EPA is associated with decreased plaque inflammation and increased stability. Atherosclerosis 212, 252259.
117. Calder, PC & Yaqoob, P (2010) Omega-3 (n-3) fatty acids, cardiovascular disease and stability of atherosclerotic plaques. Cell Mol Biol 56, 2837.
118. Galan, P, Kesse-Guyot, E, Czernichow, S et al. (2010) Effects of B vitamins and omega 3 fatty acids on cardiovascular diseases: a randomised placebo controlled trial. BMJ 341, c6273.
119. Kromhout, D, Giltay, EJ, Geleijnse, JM et al. (2010) n-3 fatty acids and cardiovascular events after myocardial infarction. N Engl J Med 363, 20152026.
120. Rauch, B, Schiele, R, Schneider, S et al. (2010) OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction. Circulation 122, 21522159.
121. Risk and Prevention Study Collaborative Group, Roncaglioni, MC, Tombesi, M, Avanzini, F et al. (2013) n-3 fatty acids in patients with multiple cardiovascular risk factors. N Engl J Med 368, 18001808.
122. Bosch, J, Gerstein, HC, Dagenais, GR et al. (2012) n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med 367, 309318.
123. Kwak, SM, Myung, SK, Lee, YJ et al. (2012) Efficacy of omega-3 fatty acid supplements (eicosapentaenoic acid and docosahexaenoic acid) in the secondary prevention of cardiovascular disease: a meta-analysis of randomized, double-blind, placebo-controlled trials. Arch Intern Med 172, 686694.
124. Kotwal, S, Jun, M, Sullivan, D et al. (2012) Omega 3 Fatty acids and cardiovascular outcomes: systematic review and meta-analysis. Circ Cardiovasc Qual Outcomes 5, 808818.
125. Rizos, EC, Ntzani, EE, Bika, E et al. (2012) Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis. J Am Med Assoc 308, 10241033.
126. Calder, PC & Yaqoob, P (2012) Marine omega-3 fatty acids and coronary heart disease. Curr Opin Cardiol 27, 412419.
127. Casula, M, Soranna, D, Catapano, AL et al. (2013) Long-term effect of high dose omega-3 fatty acidsupplementation for secondary prevention of cardiovascular outcomes: a meta-analysis of randomized, double blind, placebo controlled trials. Atheroscler Suppl 14, 243251.
128. Wen, YT, Dai, JH & Gao, Q (2014) Effects of omega-3 fatty acid on major cardiovascular events and mortality in patients with coronary heart disease: a meta-analysis of randomized controlled trials. Nutr Metab Cardiovasc Dis 24, 470475.
129. Siscovick, DS, Barringer, TA, Fretts, AM et al. (2017) Omega-3 polyunsaturated fatty acid (fish oil) supplementation and the prevention of clinical cardiovascular disease: a science advisory from the American Heart Association. Circulation 135, e867e884.
130. Gleissman, H, Johnsen, JI & Kogner, P (2010) Omega-3 fatty acids in cancer, the protectors of good and the killers of evil? Exp Cell Res 316, 13651373.
131. Merendino, N, Costantini, L, Manzi, L et al. (2013) Dietary ω−3 polyunsaturated fatty acids DHA: a potential adjuvant in the treatment of cancer. BioMed Res Int 2013; 310186.
132. Wang, D & Dubois, RN (2010) Eicosanoids and cancer. Nat Rev Cancer 10, 181193.
133. Vaughan, VC, Hassing, MR & Lewandowski, PA (2013) Marine polyunsaturated fatty acids and cancer therapy. Brit J Cancer 108, 486492.
134. Murphy, RA, Mourtzakis, M & Mazurak, VC (2012) n-3 polyunsaturated fatty acids: the potential role for supplementation in cancer. Curr Opin Clin Nutr Metab Care 15, 246251.
135. Yang, B, Wang, FL, Ren, XL et al. (2014) Biospecimen long-chain n-3 PUFA and risk of colorectal cancer: a meta-analysis of data from 60,627 individuals. PLoS ONE 9, e110574.
136. Makarem, N, Chandran, U, Bandera, EV et al. (2013) Dietary fat in breast cancer survival. Annu Rev Nutr 33, 319348.
137. Sczaniecka, AK, Brasky, TM, Lampe, JW et al. (2012) Dietary intake of specific fatty acids and breast cancer risk among postmenopausal women in the VITAL cohort. Nutr Cancer 64, 11311142.
138. Brasky, TM, Darke, AK, Song, X et al. (2013) Plasma phospholipid fatty acids and prostate cancer risk in the SELECT trial. J Natl Cancer Inst 105, 11321141.
139. Crowe, FL, Appleby, PN, Travis, RC et al. (2014) Circulating fatty acids and prostate cancer risk: individual participant meta-analysis of prospective studies. J Natl Cancer Inst 106, dju240.
140. Elia, M, Van Bokhorst-de van der Schueren, MA, Garvey, J et al. (2006) Enteral (oral or tube administration) nutritional support and eicosapentaenoic acid in patients with cancer: a systematic review. Int J Oncol 28, 523.
141. Alfano, CM, Imayama, I, Neuhouser, ML et al. (2012) Fatigue, inflammation, and ω−3 and ω−6 fatty acid intake among breast cancer survivors. J Clin Oncol 30, 12801287.
142. Cerchietti, LC, Navigante, AH & Castro, MA (2007) Effects of eicosapentaenoic and docosahexaenoic n-3 fatty acids from fish oil and preferential Cox-2 inhibition on systemic syndromes in patients with advanced lung cancer. Nutr Cancer 59, 1420.
143. van der Meij, BS, Langius, JA, Spreeuwenberg, MD et al. (2012) Oral nutritional supplements containing n-3 polyunsaturated fatty acids affect quality of life and functional status in lung cancer patients during multimodality treatment: an RCT. Eur J Clin Nutr 66, 399404.
144. Sala-Vila, A, Folkes, J & Calder, PC (2010) The effect of three lipid emulsions differing in fatty acid composition on growth, apoptosis and cell cycle arrest in the HT-29 colorectal cancer cell line. Clin Nutr 29, 519524.
145. Murphy, RA, Mourtzakis, M, Chu, QS et al. (2011) Supplementation with fish oil increases first-line chemotherapy efficacy in patients with advanced nonsmall cell lung cancer. Cancer 117, 37743780.
146. Bougnoux, P, Hajjaji, N, Ferrasson, MN et al. (2009) Improving outcome of chemotherapy of metastatic breast cancer by docosahexaenoic acid: a phase II trial. Brit J Cancer 101, 19781985.
147. Weed, HG, Ferguson, ML, Gaff, RL et al. (2011) Lean body mass gain in patients with head and neck squamous cell cancer treated perioperatively with a protein- and energy-dense nutritional supplement containing eicosapentaenoic acid. Head Neck 33, 10271033.
148. Murphy, RA, Mourtzakis, M, Chu, QS et al. (2011) Nutritional intervention with fish oil provides a benefit over standard of care for weight and skeletal muscle mass in patients with nonsmall cell lung cancer receiving chemotherapy. Cancer 117, 17751782.
149. Fearon, KC, Barber, MD, Moses, AG et al. (2006) Double-blind, placebo-controlled, randomized study of eicosapentaenoic acid diester in patients with cancer cachexia. J Clin Oncol 24, 34013407.
150. Guarcello, M, Riso, S, Buosi, R et al. (2007) EPA-enriched oral nutritional support in patients with lung cancer: effects on nutritional status and quality of life. Nutr Therap Metab 25, 2530.
151. Calder, PC, Albers, R, Antoine, JM et al. (2009) Inflammatory disease processes and interactions with nutrition. Brit J Nutr 101, Suppl. 1, S145.
152. Calder, PC, Ahluwalia, N, Albers, R et al. (2013) A consideration of biomarkers to be used for evaluation of inflammation in human nutritional studies. Brit J Nutr 109, Suppl. 1, S1S34.
153. Ross, R (1999) Atherosclerosis--an inflammatory disease. N Engl J Med 340, 115126.
154. Hansson, GK & Hermansson, A (2011) The immune system in atherosclerosis. Nat Immunol 12, 204212.
155. Calder, PC, Ahluwalia, N, Brouns, F et al. (2011) Dietary factors and low-grade inflammation in relation to overweight and obesity. Brit J Nutr 106, Suppl. 3, S5S78.
156. Colotta, F, Allavena, P, Sica, A et al. (2009) Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 30, 10731081.
157. Miles, EA & Calder, PC (2012) Influence of marine n-3 polyunsaturated fatty acids on immune function and a systematic review of their effects on clinical outcomes in rheumatoid arthritis. Brit J Nutr 107, Suppl. 2, S171S184.
158. Calder, PC (2009) Fatty acids and immune function: relevance to inflammatory bowel diseases. Int Rev Immunol 28, 506534.
159. Calder, PC (2006) n-3 polyunsaturated fatty acids, inflammation, and inflammatory diseases. Am J Clin Nutr 83, 1505S1519S.
160. Abdulrazaq, M, Innes, JK & Calder, PC (2017) Effect of ω−3 polyunsaturated fatty acids on arthritic pain: a systematic review. Nutrition 39–40, 5766.
161. Senftleber, NK, Nielsen, SM, Andersen, JR et al. (2017) Marine oil supplements for arthritis pain: a systematic review and meta-analysis of randomized trials. Nutrients 9, 42.
162. Calder, PC, Kremmyda, LS, Vlachava, M et al. (2010) Is there a role for fatty acids in early life programming of the immune system? Proc Nutr Soc 69, 373380.
163. Dunstan, JA, Mori, TA, Barden, A et al. (2003) Maternal fish oil supplementation in pregnancy reduces interleukin-13 levels in cord blood of infants at high risk of atopy. Clin Exp Allergy 33, 442448.
164. Dunstan, JA, Mori, TA, Barden, A et al. (2003) Fish oil supplementation in pregnancy modifies neonatal allergen-specific immune responses and clinical outcomes in infants at high risk of atopy: a randomized, controlled trial. J Allergy Clin Immunol 112, 11781184.
165. Noakes, PS, Vlachava, M, Kremmyda, LS et al. (2012) Increased intake of oily fish in pregnancy: effects on neonatal immune responses and on clinical outcomes in infants at 6 mo. Am J Clin Nutr 95, 395404.
166. Furuhjelm, C, Warstedt, K, Larsson, J et al. (2009) Fish oil supplementation in pregnancy and lactation may decrease the risk of infant allergy. Acta Paediatr 98, 14611467.
167. Palmer, DJ, Sullivan, T, Gold, MS et al. (2012) Effect of n-3 long chain polyunsaturated fatty acid supplementation in pregnancy on infants’ allergies in first year of life: randomised controlled trial. Brit Med J 344, e184.
168. Best, KP, Gold, M, Kennedy, D et al. (2016) Omega-3 long-chain PUFA intake during pregnancy and allergic disease outcomes in the offspring: asystematic review and meta-analysis of observational studies and randomized controlled trials. Am J Clin Nutr 103, 128143.
169. Bisgaard, H, Stokholm, J, Chawes, BL et al. (2016) Fish oil-derived fatty acids in pregnancy and wheeze and asthma in offspring. N Engl J Med 375, 25302539.
170. D'Vaz, N, Meldrum, SJ, Dunstan, JA et al. (2012) Fish oil supplementation in early infancy modulates developing infant immune responses. Clin Exp Allergy 42, 12061216.
171. Willemsen, LEM (2016) Dietary n-3 long chain polyunsaturated fatty acids in allergy prevention and asthma treatment. Eur J Pharmacol 785, 174186.
172. Klemens, CM, Berman, DR & Mozurkewich, EL (2011) The effect of perinatal omega-3 fatty acid supplementation on inflammatory markers and allergic disease: a systematic review. Brit J Obstet Gynaecol 118, 916925.
173. Miles, EA & Calder, PC (2017) Can early omega-3 fatty acid exposure reduce risk of childhood allergic disease? Nutrients 9, 784.
174. Lauritzen, L, Hansen, HS, Jorgensen, MH et al. (2001) The essentiality of long chain n-3 fatty acids in relation to development and function of the brain and retina. Prog Lipid Res 40, 194.
175. Salem, N, Litman, B, Kim, HY et al. (2001) Mechanisms of action of docosahexaenoic acid in the nervous system. Lipids 36, 945959.
176. Parletta, N, Milte, CM & Meyer, BJ (2013) Nutritional modulation of cognitive function and mental health. J Nutr Biochem 24, 725743.
177. Uauy, RD, Birch, DG, Birch, EE et al. (1990) Effect of dietary omega-3 fatty acids on retinal function of very-low-birth-weight neonates. Pediatr Res 28, 485492.
178. Birch, DG, Birch, EE, Hoffman, DR et al. (1992) Retinal development in very-low-birth-weight infants fed diets differing in omega-3 fatty acids. Invest Opthalmol Vis Sci 33, 23652376.
179. Birch, EE, Birch, DG, Hoffman, DR et al. (1992) Dietary essential fatty acid supply and visual acuity development. Invest Opthalmol Vis Sci 33, 32423253.
180. Carlson, SE, Werkman, SH, Rhodes, PG et al. (1993) Visual acuity development in healthy preterm infants: effect of marine oil supplementation. Am J Clin Nutr 58, 3542.
181. Carlson, SE, Ford, AJ, Werkman, SH et al. (1996) Visual acuity and fatty acid status of term infants fed human milk and formulas with and without docosahexaenoate and arachidonate from egg yolk lecithin. Pediatr Res 39, 882888.
182. Carlson, SE, Werkman, SH & Tolley, EA (0000) Effect of long-chain n-3 fatty acid supplementation on visual acuity and growth of preterm infants with and without bronchopulmonary dysplasia. Am J Clin Nutr 63, 687697.
183. Moon, K, Rao, SC, Schulzke, SM et al. (2016) Long-chain polyunsaturated fatty acid supplementation in preterm infants. Cochrane Database Syst Rev 12, CD000375.
184. Molloy, C, Doyle, LW, Makrides, M et al. (2012) Docosahexaenoic acid and visual functioning in preterm infants: a review. Neuropsychol Rev 22, 425437.
185. Agostoni, C, Trojan, S, Bellu, R et al. (1995) Neurodevelopmental quotient of healthy term infants at 4 months and feeding practice: the role of long-chain polyunsaturated fatty acids. Pediatr Res 38, 262266.
186. Willatts, P, Forsyth, JS, DiModugno, MK et al. (1998) Effect of long-chain polyunsaturated fatty acids in infant formula on problem solving at 10 months of age. Lancet 352, 688691.
187. Scott, DT, Janowsky, JS, Carroll, RE et al. (1998) Formula supplementation with long-chain polyunsaturatedfatty acids: are there developmental benefits? Pediatrics 102, E59.
188. Makrides, M, Neumann, MA, Simmer, K et al. (2000) A critical appraisal of the role of dietary long-chain polyunsaturated fatty acids on neural indices of term infants: a randomized, controlled trial. Pediatrics 105, 3238.
189. Auested, N, Halter, R, Hall, RT et al. (2001) Growth and development of term infants fed long-chain polyunsaturated fatty acids: a double-masked, randomized, parallel, prospective, multivariate study. Pediatrics 108, 272381.
190. Auested, N, Scott, DT, Janowsky, JS et al. (2003) Visual, cognitive, and language assessments at 39 months: a follow-up study of children fed formulas containing long-chain polyunsaturated fatty acids to 1 year of age. Pediatrics 112, e177e183.
191. Agostoni, C, Trojan, S, Bellu, R et al. (1997) Developmental quotient at 24 months and fatty acid composition of diet in early infancy: a follow up study. Arch Dis Child 1997, 76, 421424.
192. Jasani, B, Simmer, K, Patole, SK et al. (2017) Long chain polyunsaturated fatty acid supplementation in infants born at term. Cochrane Database Syst Rev 3, CD000376.
193. Gould, JF, Smithers, LG & Makrides, M (2013) The effect of maternal omega-3 (n-3) LCPUFA supplementation during pregnancy on early childhood cognitive and visual development; a systematic review and meta-analysis of randomized controlled trials. Am J Clin Nutr 97, 531544.
194. Richardson, AJ (2004) Clinical trials of fatty acid treatment in ADHD, dyslexia, dyspraxia and the autistic spectrum. Prostagland Leuk Essent Fatty Acids 70, 383390.
195. Stevens, L, Zhang, W, Peck, L et al. (2003) EFA supplementation in children with inattention, hyperactivity, and other disruptive behaviors. Lipids 38, 10071021.
196. Richardson, AJ & Puri, BK (2002) A randomized double-blind, placebo-controlled study of the effects of supplementation with highly unsaturated fatty acids on ADHD-related symptoms in children with specific learning difficulties. Prog Neuropsychopharmacol Biol Psych 26, 233239.
197. Yui, K, Koshiba, M, Nakamura, S et al. (2012) Effects of large doses of arachidonic acid added to docosahexaenoic acid on social impairment in individuals with autism spectrum disorders: a double-blind, placebo-controlled, randomized trial. J Clin Psychopharmacol 32, 200206.
198. Meguid, NA, Atta, HM, Gouda, AS et al. (2008) Role of polyunsaturated fatty acids in the management of Egyptian children with autism. Clin Biochem 41, 10441048.
199. Perera, H, Jeewandara, KC, Seneviratne, S et al. (2012) Combined ω3 and ω6 supplementation in children with attention-deficit hyperactivity disorder (ADHD) refractory to methylphenidate treatment: a double-blind, placebo-controlled study. J Child Neurol 27, 747753.
200. Milte, CM, Parletta, N, Buckley, JD et al. (2012) Eicosapentaenoic and docosahexaenoic acids, cognition, and behavior in children with attention-deficit/hyperactivity disorder: a randomized controlled trial. Nutrition 28, 670677.
201. Gustafsson, PA, Birberg-Thornberg, U, Duchén, K et al. (2010) EPA supplementation improves teacher-rated behaviour and oppositional symptoms in children with ADHD. Acta Paediatr 99, 15401549.
202. Bélanger, SA, Vanasse, M, Spahis, S et al. (2009) Omega-3 fatty acid treatment of children with attention-deficit hyperactivity disorder: a randomized, double-blind, placebo-controlled study. Paediatr Child Health 14, 8998.
203. Sorgi, PJ, Hallowell, EM, Hutchins, HL et al. (2007) Effects of an open-label pilot study with high-dose EPA/DHA concentrates on plasma phospholipids and behavior in children with attention deficit hyperactivity disorder. Nutr J 6, 16.
204. Bos, DJ, Oranje, B, Veerhoek, ES et al. (2015) Reduced symptoms of inattention after dietary omega-3 fatty acid supplementation in boys with and without attention deficit/hyperactivity disorder. Neuropsychopharmacol 40, 22982306.
205. Sheppard, KW, Boone, KM, Gracious, B et al. (2017) Effect of omega-3 and -6 supplementation on language in preterm toddlers exhibiting autism spectrum disorder symptoms. J Autism Dev Disord (In the Press).
206. Voigt, RG, Llorente, AM, Jensen, CL et al. (2001) A randomized, double-blind, placebo-controlled trial of docosahexaenoic acid supplementation in children with attention-deficit/hyperactivity disorder. J Pediatr 139, 189196.
207. Hirayama, S, Hamazaki, T & Terasawa, K (2004) Effect of docosahexaenoic acid-containing food administration on symptoms of attention-deficit/hyperactivity disorder - a placebo-controlled double-blind study. Eur J Clin Nutr 58, 467473.
208. Bent, S, Bertoglio, K, Ashwood, P et al. (2011) A pilot randomized controlled trial of omega-3 fatty acids for autism spectrum disorder. J Autism Dev Disord 41, 545554.
209. Politi, P, Cena, H, Comelli, M et al. (2008) Behavioral effects of omega-3 fatty acid supplementation in young adults with severe autism: an open label study. Arch Med Res 39, 682685.
210. Amminger, GP, Berger, GE, Schäfer, MR et al. (2007) Omega-3 fatty acids supplementation in children with autism: a double-blind randomized, placebo-controlled pilot study. Biol Psychiatry 61, 551553.
211. Johnson, M, Ostlund, S, Fransson, G et al. (2009) Omega-3/omega-6 fatty acids for attention deficit hyperactivity disorder: a randomized placebo-controlled trial in children and adolescents. J Atten Disord 12, 394401.
212. Raz, R, Carasso, RL & Yehuda, S (2009) The influence of short-chain essential fatty acids on children with attention-deficit/hyperactivity disorder: a double-blind placebo-controlled study. J Child Adolesc Psychopharmacol 19, 167177.
213. Voigt, RG, Mellon, MW, Katusic, SK et al. (2014) Dietary docosahexaenoic acid supplementation in children with autism. J Pediatr Gastroenterol Nutr 58, 715722.
214. Mankad, D, Dupuis, A, Smile, S et al. (2015) A randomized, placebo controlled trial of omega-3 fatty acids in the treatment of young children with autism. Mol Autism 6, 18.
215. Frensham, LJ, Bryan, J & Parletta, N (2012) Influences of micronutrient and omega-3 fatty acid supplementation on cognition, learning, and behaviour: methodological considerations and implications for children and adolescents in developed societies. Nutr Rev 70, 594610.
216. Horvath, A, Łukasik, J & Szajewska, H (2017) ω−3 Fatty acid supplementation does not affect autism spectrum disorder in children: a systematic review and meta-analysis. J Nutr 147, 367376.
217. Mazahery, H, Stonehouse, W, Delshad, M et al. (2017) Relationship between long chain n-3 polyunsaturated fatty acids and autism spectrum disorder: systematic review and meta-analysis of case-control and randomised controlled trials. Nutrients 9, 155.
218. Cooper, RE, Tye, C, Kuntsi, J et al. (2016) The effect of omega-3 polyunsaturated fatty acid supplementation on emotional dysregulation, oppositional behaviour and conduct problems in ADHD: a systematic review and meta-analysis. J Affect Disord 190, 474482.
219. Chang, JC, Su, KP, Mondelli, V et al. (2017) Omega-3 polyunsaturated fatty acids in youths with attention deficit hyperactivity disorder (ADHD): A systematic review and meta-analysis of clinical trials and biological studies. Neuropsychopharmacol (In the Press).
220. Derbyshire, E (2017) Do omega-3/6 fatty acids have a therapeutic role in children and young people with ADHD? J Lipids (In the Press).
221. Rudin, DO (1981) The major psychoses and neuroses as omega-3 essential fatty acid deficiency syndrome: substrate pellagra. Biol Psychiatry 16, 837850.
222. Hibbeln, JR (1998) Fish consumption and major depression. Lancet 351, 1213.
223. Su, KP, Huang, SY, Chiu, CC et al. (2003) Omega-3 fatty acids in major depressive disorder. A preliminary double-blind, placebo-controlled trial. Eur Neuropsychopharmacol 13, 267271.
224. Marangell, LB, Martinez, JM, Zboyan, HA et al. (2003) A double-blind, placebo-controlled study of the omega-3 fatty acid docosahexaenoic acid in the treatment of major depression. Am J Psychiatry 160, 996998.
225. Stoll, AL, Severus, WE, Freeman, MP et al. (1999) Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial. Arch Gen Psychiatry 56, 407412.
226. Nemets, B, Stahl, Z & Belmaker, RH (2002) Addition of omega-3 fatty acid to maintenance medication treatment for recurrent unipolar depressive disorder. Am J Psychiatry 159, 477479.
227. Mocking, RJ, Harmsen, I, Assies, J et al. (2016) Meta-analysis and meta-regression of omega-3 polyunsaturated fatty acid supplementation for major depressive disorder. Transl Psychiatry 6, e756.
228. Sublette, ME, Ellis, SP, Geant, AL et al. (2012) Meta-analysis of the effects of eicosapentaenoic acid (EPA) in clinical trials in depression. J Clin Psychiatry 72, 15771584.
229. Sarris, J, Mischoulon, D & Schweitzer, I (2012) Omega-3 for bipolar disorder: meta-analyses of use in mania and bipolar depression. J Clin Psychiatry 73, 8186.
230. Appleton, KM, Sallis, HM, Perry, R et al. (2016) ω−3 Fatty acids for major depressive disorder in adults: an abridged Cochrane review. BMJ Open 6, e010172.
231. Peet, M, Laugharne, J, Rangarajan, N et al. (1995) Depleted red cell membrane essential fatty acids in drug-treated schizophrenic patients. J Psychiatr Res 29, 227232.
232. Yao, JK, van Kammen, DP & Welker, JA (1994) Red blood cell membrane dynamics in schizophrenia. II. Fatty acid composition. Schizophr Res 13, 217226.
233. Glen, AI, Glen, EM, Horrobin, DF et al. (1994) A red cell membrane abnormality in a subgroup of schizophrenic patients: evidence for two diseases. Schizophr Res 12, 5361.
234. Edwards, R, Peet, M, Shay, J et al. (1998) Omega-3 polyunsaturated fatty acid levels in the diet and in red blood cell membranes of depressed patients. J Affect Disord 48, 149155.
235. Hoen, WP, Lijmer, JG, Duran, M et al. (2013) Red blood cell polyunsaturated fatty acids measured in red blood cells and schizophrenia: a meta-analysis. Psychiatry Res 207, 112.
236. Peet, M, Brind, J, Ramchand, CN et al. (2001) Two double-blind placebo-controlled pilot studies of eicosapentaenoic acid in the treatment of schizophrenia. Schizophr Res 49, 243251.
237. Peet, M & Horrobin, DF (2002) A dose-ranging study of the effects of ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs. Arch Gen Psychiatry 59, 913919.
238. Fenton, WS, Dickerson, F, Boronow, J et al. (2001) A placebo-controlled trial of omega-3 fatty acid (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia. Am J Psychiatry 158, 20712074.
239. Emsley, R, Myburgh, C, Oosthuizen, P et al. (2002) Randomized, placebo-controlled study of ethyl-eicosapentaenoic acid as supplemental treatment in schizophrenia. Am J Psychiatry 159, 15961598.
240. Pawełczyk, T, Grancow-Grabka, M, Kotlicka-Antczak, M et al. (2016) A randomized controlled study of the efficacy of six-month supplementation with concentrated fish oil rich in omega-3 polyunsaturated fatty acids in first episode schizophrenia. J Psychiatr Res 73, 3444.
241. Joy, CB, Mumby-Croft, R & Joy, LA (2006) Polyunsaturated fatty acid supplementation for schizophrenia. Cochrane Database Syst Rev 3, CD001257.
242. Zanarini, MC & Frankenburg, FR (2003) N-3 fatty acid treatment of women with borderline personality disorder: a double-blind, placebo-controlled pilot study. Am J Psychiatry 160, 167169.
243. Hamazaki, T, Sawazaki, S, Itomura, M et al. (1996) The effect of docosahexaenoic acid on aggression in young adults. A placebo-controlled double-blind study. J Clin Invest 97, 11291133.
244. Hamazaki, T, Thienprasert, A, Kheovichai, K et al. (2002) The effect of docosahexaenoic acid on aggression in elderly Thai subjects--a placebo-controlled double-blind study. Nutr Neurosci 5, 3741.
245. Prasad, MR, Lovell, MA, Yatin, M et al. (1998) Regional membrane phospholipid alterations in Alzheimer's disease. Neurochem Res 23, 8188.
246. Tully, AM, Roche, HM, Doyle, R et al. (2003) Low serum cholesteryl ester-docosahexaenoic acid levels in Alzheimer's disease: a case-control study. Brit J Nutr 89, 483489.
247. Cunnane, SC, Schneider, JA, Tangney, C et al. (2012) Plasma and brain fatty acid profile in mild cognitive impairment and Alzheimer's disease. J Alzheimers Dis 29, 691697.
248. Soderberg, M, Edlund, C, Kristensson, K et al. (1991) Fatty acid composition of brain phospholipids in aging and in Alzheimer's disease. Lipids 26, 421425.
249. Conquer, JA, Tierney, MC, Zecevic, J et al. (2000) Fatty acid analysis of blood plasma of patients with Alzheimer's disease, other types of dementia, and cognitive impairment. Lipids 35, 13051312.
250. Sinn, N, Milte, CM, Street, SJ et al. (2012) Effects of n-3 fatty acids, EPA v. DHA, on depressive symptoms, quality of life, memory and executive function in older adults with mild cognitive impairment: a 6-month randomised controlled trial. Brit J Nutr 107, 16821693.
251. Scheltens, P, Twisk, JW, Blesa, R et al. (2012) Efficacy of Souvenaid in mild Alzheimer's disease: results from a randomized, controlled trial. J Alzheimers Dis 31, 225236.
252. Quinn, JF, Raman, R, Thomas, RG et al. (2010) Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. J Am Med Assoc 304, 19031911.
253. Freund-Levi, Y, Eriksdotter-Jönhagen, M, Cederholm, T et al. (2006) Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial. Arch Neurol 63, 14021408.
254. Freund-Levi, Y, Basun, H, Cederholm, T et al. (2008) Omega-3 supplementation in mild to moderate Alzheimer's disease: effects on neuropsychiatric symptoms. Int J Geriatr Psychiatry 23, 161169.
255. Kotani, S, Sakaguchi, E, Warashina, S et al. (2006) Dietary supplementation of arachidonic and docosahexaenoic acids improves cognitive dysfunction. Neurosci Res 56, 159164.
256. Boston, PF, Bennett, A, Horrobin, DF et al. (2204) Ethyl-EPA in Alzheimer's disease - a pilot study. Prostagland Leukot Essent Fatty Acids 71, 341346.
257. Phillips, MA, Childs, CE, Calder, PC et al. (2015) No effect of omega-3 fatty acid supplementation on cognition and mood in individuals with cognitive impairment and probable Alzheimer's disease: a randomised controlled trial. Int J Mol Sci 16, 2460024613.
258. Sydenham, E, Dangour, AD & Lim, WS (2012) Omega 3 fatty acid for the prevention of cognitive decline and dementia. Cochrane Database Syst Rev 6, CD005379.
259. Zhang, XW, Hou, WS, Li, M et al. (2016) Omega-3 fatty acids and risk of cognitive decline in the elderly: a meta-analysis of randomized controlled trials. Aging Clin Exp Res 28, 165166.
260. Burckhardt, M, Herke, M, Wustmann, T et al. (2016) Omega-3 fatty acids for the treatment of dementia. Cochrane Database Syst Rev 4, CD009002.
261. Andrieu, S, Guyonnet, S, Coley, N et al. (2017) Effect of long-term omega 3 polyunsaturated fatty acid supplementation with or without multidomain intervention on cognitive function in elderly adults with memory complaints (MAPT): a randomised, placebo-controlled trial. Lancet Neurol 16, 377389.
262. Simopolous, AP, Leaf, A & Salem, N (1999) Essentiality and recommended dietary intakes for omega-6 and omega-3 fatty acids. Ann Nutr Metab 43, 127130.
263. International Society for the Study of Fatty Acids and Lipids (2004) Recommendations for the intake of polyunsaturated fatty acids in healthy adults (ISSFAL Policy Statement 3). http://www.issfal.org/news-links/resources/publications/PUFAIntakeReccomdFinalReport.pdf.
264. French Agency for Food, Environmental and Occupational Health Safety (2003) The omega-3 fatty acids and the cardiovascular system: nutritional benefits and claims. http://www.afssa.fr?Documents?NUT-Ra-omega3EN.pdf.
265. National Health and Medical Research Council (2006) Nutrient reference values for Australia and New Zealand including recommended dietary intakes. http://www.nhmrc.gov.au/publications/synopses/n35syn.htm.
266. Food and Agricultural Organisation of the United Nations (2010) Fat and Fatty Acids in Human Nutrition: report of an Expert Consultation. Food and Agricultural Organisation of the United Nations, Rome.
267. European Food Safety Authority (2010) Scientific opinion on dietary reference values for fats, including saturated fatty acids, polyunsaturated fatty acids, monounsaturated fatty acids, trans fatty acids and cholesterol. EFSA J 8, 1461.
268. Mori, TA & Woodman, RJ (2006) The independent effects of eicosapentaenoic acid and docosahexaenoic acid on cardiovascular risk factors in humans. Curr Opin Clin Nutr Metab Care 9, 95104.
269. Wei, MY & Jacobson, TA (2011) Effects of eicosapentaenoic acid versus docosahexaenoic acid on serum lipids: a systematic review and meta-analysis. Curr Atheroscler Rep 13, 474483.
270. Schuchardt, JP & Hahn, A (2013) Bioavailability of long-chain omega-3 fatty acids. Prostaglandins Leukot Essent Fatty Acids 89, 18.
271. Ghasemifard, S, Turchini, GM & Sinclair, AJ (2014) Omega-3 long chain fatty acid ‘bioavailability’: a review of evidence and methodological considerations. Prog Lipid Res 56, 92108.
272. Raatz, SK, Johnson, LK & Bukowski, MR (2016) Enhanced bioavailability of EPA from emulsified fish oil preparations versus capsular triacylglycerol. Lipids 51, 643651.
273. Ruiz-Lopez, N, Usher, S, Sayanova, OV et al. (2015) Modifying the lipid content and composition of plant seeds: engineering the production of LC-PUFA. Appl Microbiol Biotechnol 99, 143154.
274. Walker, CG, Jebb, SA & Calder, PC (2013) Stearidonic acid as a supplemental source of ω−3 polyunsaturated fatty acids to enhance status for improved human health. Nutrition 29, 363369.
275. James, MJ, Ursin, VM & Cleland, LG (2003) Metabolism of stearidonic acid in human subjects: comparison with the metabolism of other n-3 fatty acids. Am J Clin Nutr 77, 11401145.

Keywords

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed